These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18393845)

  • 21. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"].
    Tamaoka A
    Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease.
    Scheinin NM; Scheinin M; Rinne JO
    Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):265-79. PubMed ID: 21532540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain.
    Henderson BW; Gentry EG; Rush T; Troncoso JC; Thambisetty M; Montine TJ; Herskowitz JH
    J Neurochem; 2016 Aug; 138(4):525-31. PubMed ID: 27246255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease.
    Savelieff MG; DeToma AS; Derrick JS; Lim MH
    Acc Chem Res; 2014 Aug; 47(8):2475-82. PubMed ID: 25080056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid biomarkers in Alzheimer's disease.
    Blennow K; Mattsson N; Schöll M; Hansson O; Zetterberg H
    Trends Pharmacol Sci; 2015 May; 36(5):297-309. PubMed ID: 25840462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aβ toxicity in Alzheimer's disease.
    Cavallucci V; D'Amelio M; Cecconi F
    Mol Neurobiol; 2012 Apr; 45(2):366-78. PubMed ID: 22415442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular amyloid-β accumulation in calcium-binding protein-deficient neurons leads to amyloid-β plaque formation in animal model of Alzheimer's disease.
    Moon M; Hong HS; Nam DW; Baik SH; Song H; Kook SY; Kim YS; Lee J; Mook-Jung I
    J Alzheimers Dis; 2012; 29(3):615-28. PubMed ID: 22269161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Toxicity and Polymorphism of β-Amyloid Oligomers.
    Huang YR; Liu RT
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards an understanding of amyloid-β oligomers: characterization, toxicity mechanisms, and inhibitors.
    Lee SJ; Nam E; Lee HJ; Savelieff MG; Lim MH
    Chem Soc Rev; 2017 Jan; 46(2):310-323. PubMed ID: 27878186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment.
    Portelius E; Mattsson N; Andreasson U; Blennow K; Zetterberg H
    Curr Pharm Des; 2011; 17(25):2594-602. PubMed ID: 21728980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage.
    Ferrera D; Mazzaro N; Canale C; Gasparini L
    Neurobiol Aging; 2014 Nov; 35(11):2444-2457. PubMed ID: 24973120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?
    Klein WL
    J Alzheimers Dis; 2013; 33 Suppl 1():S49-65. PubMed ID: 22785404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptides as Potential Therapeutics for Alzheimer's Disease.
    Ribarič S
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease.
    Pandya S; Kuceyeski A; Raj A;
    J Alzheimers Dis; 2017; 55(4):1639-1657. PubMed ID: 27911289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer's Disease.
    Pyun JM; Kang MJ; Ryoo N; Suh J; Youn YC; Park YH; Kim S
    J Alzheimers Dis; 2020; 75(3):685-696. PubMed ID: 32390633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyroglutamate-Aβ: role in the natural history of Alzheimer's disease.
    Gunn AP; Masters CL; Cherny RA
    Int J Biochem Cell Biol; 2010 Dec; 42(12):1915-8. PubMed ID: 20833262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease.
    Cai Z; Hussain MD; Yan LJ
    Int J Neurosci; 2014 May; 124(5):307-21. PubMed ID: 23930978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
    Brody DL; Jiang H; Wildburger N; Esparza TJ
    Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
    Murakami K
    Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms of neurodegeneration in Alzheimer's disease.
    Crews L; Masliah E
    Hum Mol Genet; 2010 Apr; 19(R1):R12-20. PubMed ID: 20413653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.